Report : North America Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Treatment Type (Antimalarial Agents, and Diagnostic Test); Route of Administration (Oral, and Parenteral); End User (Hospitals, Specialty Clinics, and Others)
At 4.5% CAGR, the North America Malaria Treatment Market is speculated to be worth US$ 996.80 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America malaria treatment market was valued at US$ 765.63 million in 2022 and is expected to reach US$ 996.80 million by 2028, registering a CAGR of 4.5% from 2022 to 2028. Extending pipeline of new drugs and vaccines and rapid diagnostic tests are the critical factors attributed to the North America malaria treatment market expansion.
Antimicrobial resistance threatens the public health response to many diseases, such as malaria, and the R&D of new medicines is the best strategy to overcome this challenge. With this, the antimalarial drug/vaccine pipeline is becoming increasingly robust. Public–private partnerships are accelerating research activities in the malaria treatment market, creating lucrative opportunities for the market growth. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, is working with many pharmaceutical companies to reduce the burden of malaria by developing novel treatment options. In December 2019, Ipca Laboratories collaborated with MMV to develop Atoguanil, a novel antimalarial coformulation. So, extending pipeline of new drugs and vaccines is expected to drive the North America malaria treatment market.
On the contrary, counterfeit antimalarial drugs and subsequent drug resistance hurdles the growth of North America malaria treatment market.
Based on treatment, the North America malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held 39.4% market share in 2022, amassing US$ 301.61 million. It is projected to garner US$ 381.88 million by 2028 to expand at 4.0% CAGR during 2022–2028. Further, prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.
Based on drug type, the North America malaria treatment market is bifurcated into branded and generic. The generic segment held 59.5% market share in 2022, amassing US$ 455.51 million. It is projected to garner US$ 584.05 million by 2028 to expand at 4.2% CAGR during 2022–2028.
Based on route of administration, the North America malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held 69.5% market share in 2022, amassing US$ 531.81 million. It is projected to garner US$ 682.79 million by 2028 to expand at 4.3% CAGR during 2022–2028.
Based on distribution channel, the North America malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 43.3% market share in 2022, amassing US$ 331.23 million. It is projected to garner US$ 432.72 million by 2028 to expand at 4.6% CAGR during 2022–2028.
Based on end user, the North America malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held 44.8% market share in 2022, amassing US$ 343.13 million. It is projected to garner US$ 441.34 million by 2028 to expand at 4.3% CAGR during 2022–2028.
Based on country, the North America malaria treatment market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% market share in 2022. It was assessed at US$ 649.02 million in 2022 and is likely to hit US$ 838.41 million by 2028, exhibiting a CAGR of 4.4% during the forecast period.
Key players dominating the North America malaria treatment market are AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, VLP Therapeutics LLC, and Zydus Healthcare Ltd, among others.
- In Dec 2021, Drug maker Cadila Healthcare (Zydus Cadila), announced its antimalarial drug ZY19489 (MMV253), currently in development together with Medicines for Malaria Venture (MMV), received orphan drug designation from the USFDA.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com